Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intellia Therapeutics (NTLA – Research Report), Tango Therapeutics (TNGX – Research Report) and Nuvalent (NUVL – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Intellia Therapeutics (NTLA)
TD Cowen analyst Joseph Thome maintained a Buy rating on Intellia Therapeutics today. The company’s shares closed last Thursday at $13.76.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $16.38.
See the top stocks recommended by analysts >>
Tango Therapeutics (TNGX)
In a report released today, Laura Prendergast from Stifel Nicolaus maintained a Buy rating on Tango Therapeutics. The company’s shares closed last Thursday at $11.09, close to its 52-week high of $12.02.
According to TipRanks.com, Prendergast is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $17.00 average price target, which is a 35.2% upside from current levels. In a report issued on February 23, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $19.00 price target.
Nuvalent (NUVL)
LifeSci Capital analyst Charles Zhu maintained a Buy rating on Nuvalent today and set a price target of $142.00. The company’s shares closed last Thursday at $102.87.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
Currently, the analyst consensus on Nuvalent is a Strong Buy with an average price target of $141.20, implying a 33.4% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $126.00 price target.
